Black checkmark with a sparkle and a curved line underneath on a white background.
Company

PMV Pharmaceuticals, Inc.

Ticker
PMVP
Sector
Industry
Report date
November 10, 2026
Valye AI Score

91

Very high visibility
Recent developments
Recent developments summary

Recent developments for PMV Pharmaceuticals include clinical progress in its PYNNACLE trial, management changes, financing activities, and stock price volatility.

Recent developments:
  • PMV Pharmaceuticals named an interim medical chief ahead of a planned Phase 3 cancer trial, indicating advancement in clinical development planning [N1].
  • The company appointed a chief commercial officer in preparation for the rezatapopt NDA filing [N5].
  • Interim Phase 2 PYNNACLE ovarian cancer data was reported, supporting ongoing clinical progress [N6].
  • PMV completed a $50.8 million public offering in August 2026 to fund operations and development [S2].
  • The stock experienced a 26% decline over four weeks in mid-2026, followed by a 19% rise over three months later in 2026, reflecting market volatility [N3][N2].
  • PMV Pharmaceuticals has been active in investor conferences discussing oncology innovation and healthcare advances [N5].
Overview

PMV Pharmaceuticals, Inc. is a biotechnology company specializing in precision oncology therapies that target mutant forms of the tumor suppressor protein p53, which is mutated in about half of all cancers. Founded in 2013, the company has concentrated on research and development of its lead product candidate, rezatapopt, designed to restore wild-type function to the p53 Y220C mutation. The company initiated the PYNNACLE Phase 1/2 clinical trial in 2020, with the Phase 2 portion intended as a registrational pivotal study. Rezatapopt has received FDA Fast Track and Orphan Drug Designations. PMV Pharmaceuticals has no approved products or revenue and relies on equity offerings and collaborations to fund operations. It uses third-party service providers for clinical development and manufacturing and plans to build or contract commercial capabilities upon regulatory approval.

Executive summary

PMV Pharmaceuticals, Inc. is a clinical-stage precision oncology company focused on developing small molecule therapies targeting mutant p53 proteins, with its lead candidate rezatapopt in Phase 2 pivotal trials. The company has no approved products or revenue and continues to incur significant losses. As of September 30, 2026, it held approximately $108.5 million in cash, cash equivalents, and marketable securities, supporting operations for at least one year. Recent developments include clinical progress in the PYNNACLE trial, management appointments, and a public offering raising $50.8 million gross proceeds. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for PMVP

Bull case model:

The company's lead candidate rezatapopt has advanced to a pivotal Phase 2 clinical trial with FDA Fast Track and Orphan Drug designations, indicating regulatory recognition of its potential. Successful completion of the PYNNACLE trial and NDA submission could enable accelerated approval for platinum-resistant ovarian cancer. The company's strong liquidity position following recent financing supports ongoing development and operational activities. Management appointments in clinical and commercial roles suggest preparation for potential product commercialization. Continued clinical progress and regulatory milestones could enhance the company's value proposition.

Bear case model:

PMV Pharmaceuticals has no approved products or revenue and has incurred significant losses since inception, with ongoing substantial research and development expenses. Clinical development carries inherent risks including safety, efficacy, and regulatory approval uncertainties. The company depends on external financing to fund operations, and failure to secure adequate capital could delay or halt development. The absence of a current commercial infrastructure requires building or contracting capabilities, which may pose execution challenges. Market volatility and competitive oncology landscape add to operational risks.

Moat:

PMV Pharmaceuticals' moat is based on its proprietary precision oncology platform targeting mutant p53 proteins, leveraging over four decades of foundational research including the discovery of p53 by its co-founder. Its lead candidate rezatapopt targets a specific p53 mutation (Y220C) with potential tumor-agnostic applications. The company's specialized focus and clinical progress, including FDA Fast Track and Orphan Drug designations, contribute to its competitive positioning in a challenging oncology drug development landscape. However, the moat is contingent on successful clinical and regulatory outcomes and the ability to commercialize its therapies.

Risks overview
Risks summary
The primary risks for PMV Pharmaceuticals center on clinical and regulatory uncertainties for its lead candidate, financial sustainability dependent on external funding, and challenges in commercializing novel oncology therapies.
Risks details:

• Clinical Development Risk: The success of rezatapopt and other product candidates depends on clinical trial outcomes, which are uncertain and may not demonstrate safety or efficacy sufficient for regulatory approval.
• Regulatory Risk: Obtaining FDA approval involves complex processes and the possibility of delays or denials, impacting the company's ability to commercialize its therapies.
• Financial Risk: The company has a history of net losses and relies on external financing; inability to raise capital on acceptable terms could impair operations and development programs.
• Commercialization Risk: PMV Pharmaceuticals currently lacks a sales force and commercial infrastructure, requiring development or partnerships to successfully market any approved products.
• Market and Competitive Risk: The oncology therapeutics market is highly competitive with rapid innovation; competitors may develop superior therapies targeting mutant p53 or other mechanisms.

FINAL FORECAST FOR PMVP

Final take one line
PMV Pharmaceuticals is a clinical-stage precision oncology company with clear development progress and strong liquidity but faces typical biotech risks related to clinical, regulatory, and financial uncertainties.
Final take 12 to 24 month view

Business trends: Continued clinical development of rezatapopt targeting mutant p53 with regulatory designations and planned NDA submission; active investor engagement and financing activities.
Execution milestones: Completion of Phase 2 PYNNACLE trial enrollment, NDA filing planned for Q1 2027, management appointments for clinical and commercial readiness.
Key risks: Clinical trial outcomes and regulatory approval uncertainties, dependence on external financing, and challenges in building commercial infrastructure.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

91
LLM visibility overview
LLM Visibility known facts
  • PMV Pharmaceuticals, Inc. is a precision oncology company focused on discovery and development of small molecule, tumor-agnostic therapies targeting mutant p53 proteins, which are implicated in approximately half of all cancers.
  • The company was founded in March 2013 and has devoted its efforts primarily to research and development and capital raising, with no approved products or revenue to date.
  • Its lead product candidate is rezatapopt, which targets the p53 Y220C mutation and is being developed through the PYNNACLE Phase 1/2 clinical trial initiated in October 2020.
  • Rezatapopt received FDA Fast Track designation in October 2020 and Orphan Drug Designation in March 2026 for treatment of TP53 Y220C positive ovarian, fallopian tube, and primary peritoneal cancers.
  • The Phase 2 portion of the PYNNACLE trial is intended as a registrational pivotal study, with enrollment of platinum-resistant/refractory ovarian cancer patients for primary analysis completed.
  • The company plans to submit an initial New Drug Application (NDA) via accelerated approval for platinum resistant/refractory ovarian cancer in Q1 2027.
  • PMV Pharmaceuticals does not currently have a sales force or commercial infrastructure and plans to use third-party service providers for clinical development and manufacturing.
  • The company has incurred net losses every year since inception and reported a net loss of $34.4 million for the three months ended September 30, 2026, and $70.5 million for the nine months ended September 30, 2026.
  • As of September 30, 2026, PMV Pharmaceuticals had cash and cash equivalents of approximately $20.0 million, short-term investments of approximately $82.6 million, total current assets of approximately $104.9 million, and current liabilities of approximately $10.7 million, resulting in a current ratio of 9.81 and a cash ratio of 9.59.
  • The company completed a public offering in August 2026 raising gross proceeds of approximately $50.8 million and net proceeds of approximately $46.9 million.
  • Management concluded there is no longer substantial doubt about the company's ability to continue as a going concern based on available liquidity resources including the August 2026 offering proceeds.
  • Research and development expenses decreased to $16.1 million for Q3 2026 from $18.2 million in Q3 2025, primarily due to lower contract research organization costs related to rezatapopt.
  • General and administrative expenses decreased slightly to $4.0 million for Q3 2026 from $4.3 million in Q3 2025, with lower legal and consulting fees partially offset by higher personnel and facility expenses.
  • Interest income decreased to $0.8 million for Q3 2026 from $1.5 million in Q3 2025 due to lower average invested balances.
  • The company recognized a $12.8 million loss from change in fair value of warrant liability in Q3 2026 related to the August 2026 public offering warrants.
  • Recent news highlights include management changes such as naming an interim medical chief ahead of a planned Phase 3 cancer trial, and the appointment of a chief commercial officer ahead of the rezatapopt NDA filing.
  • The company has reported interim Phase 2 PYNNACLE ovarian cancer data and progress in clinical development, with presentations at major oncology conferences.
  • PMV Pharmaceuticals has been active in investor conferences discussing oncology innovation and healthcare advances.
  • The stock has experienced volatility with a 26% loss over four weeks reported in mid-2026 and a 19% rise over three months reported in late 2026.
  • The company filed a $200 million mixed securities shelf in late 2024 to support financing activities.
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-06 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-10-28 | www.nasdaq.com | Cardiff Names Alland Interim Medical Chief Ahead Of Planned Phase 3 Cancer Trial | https://www.nasdaq.com/articles/cardiff-names-alland-interim-medical-chief-ahead-planned-phase-3-cancer-trial
  • N2 | 2026-10-12 | www.nasdaq.com | PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know | https://www.nasdaq.com/articles/pmvp-stock-rises-19-3-months-heres-what-you-need-know
  • N3 | 2026-06-10 | www.nasdaq.com | PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner | https://www.nasdaq.com/articles/pmv-pharmaceuticals-pmvp-loses-26-4-weeks-heres-why-trend-reversal-may-be-around-corner
  • N4 | 2025-08-07 | www.nasdaq.com | PMV Pharmaceuticals (PMVP) Q2 Loss Jumps | https://www.nasdaq.com/articles/pmv-pharmaceuticals-pmvp-q2-loss-jumps
  • N5 | 2025-05-23 | www.nasdaq.com | PMV Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences on Oncology Innovation and Healthcare Advances | https://www.nasdaq.com/articles/pmv-pharmaceuticals-inc-present-upcoming-investor-conferences-oncology-innovation-and
  • N6 | 2025-05-09 | www.nasdaq.com | PMV Pharmaceuticals Reports Progress in Phase 2 PYNNACLE Trial and First Quarter 2025 Financial Results | https://www.nasdaq.com/articles/pmv-pharmaceuticals-reports-progress-phase-2-pynnacle-trial-and-first-quarter-2025
  • N7 | 2025-03-05 | www.nasdaq.com | Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing | https://www.nasdaq.com/articles/heres-why-pmv-pharmaceuticals-pmvp-looks-ripe-bottom-fishing
  • N8 | 2025-03-03 | www.nasdaq.com | PMV Pharmaceuticals, Inc. Full Year Loss Narrows | https://www.nasdaq.com/articles/pmv-pharmaceuticals-inc-full-year-loss-narrows
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine